Enlivex Therapeutics Ltd.
ENLVDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Feb 2027
Market Overview
Stock performance and key metrics
2 upcoming, 0 past
ENLV Earnings Report
EPS Est: $-0.02 | FQ end 2026-03
1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Allocetra | Phase 2 | Osteoarthritis, Knee | - | - |
Allocetra-OTS | Phase 2 | Sepsis | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Enlivex Therapeutics Ltd.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Enlivex Therapeutics Ltd.'s (ENLV) pipeline across Phase 2. Its lead program is Allocetra (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Enlivex Therapeutics Ltd.'s next FDA catalyst?→
Enlivex Therapeutics Ltd.'s (ENLV) next tracked catalyst is a Earnings expected July 3, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ENLV biotech catalysts?→
Add ENLV to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Enlivex Therapeutics Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.